iNtRON Biotechnology, Inc. Logo

iNtRON Biotechnology, Inc.

Develops phage therapeutics and molecular diagnostics to combat infectious diseases.

048530 | KO

Overview

Corporate Details

ISIN(s):
KR7048530000
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 사기막골로 137 중앙인더스피아 5차 701~704호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

iNtRON Biotechnology, Inc. is a biopharmaceutical company specializing in the development of novel drugs and molecular diagnostics. The company is a recognized leader in bacteriophage and endolysin-based technologies, focusing on creating innovative therapeutics to combat infectious diseases, including antibiotic-resistant super-bacteria. Its core activities encompass the development of 'first-in-class' biopharmaceutical pipelines, such as its PHAGERIA® platform, which targets the gut microbiome. In addition to therapeutics, iNtRON develops and manufactures molecular diagnostic assays and reagents for human and animal diseases, utilizing technologies like real-time PCR. The company aims to be a global R&D leader in the immune and immunotherapeutics market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 91.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-06-12 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.3 KB
2025-06-12 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 20.1 KB
2025-05-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-14 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.1 KB
2025-04-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.1 KB
2025-04-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.0 KB
2025-04-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.0 KB
2025-04-09 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 20.1 KB
2025-04-09 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 20.8 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.7 KB
2025-03-19 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.6 KB
2025-03-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.2 KB

Automate Your Workflow. Get a real-time feed of all iNtRON Biotechnology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for iNtRON Biotechnology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for iNtRON Biotechnology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN
Lineage Cell Therapeutics Inc. Logo
Developing off-the-shelf cell therapies for neurological and ophthalmic conditions.
Israel
LCTX
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipocine Inc. Logo
Biopharma developing oral drugs for metabolic & endocrine disorders using delivery technology.
United States of America
LPCN
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
Liquidia Corp Logo
Develops inhaled therapies for rare cardiopulmonary diseases using proprietary PRINT® technology.
United States of America
LQDA

Talk to a Data Expert

Have a question? We'll get back to you promptly.